• Users Online: 137
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 16  |  Issue : 1  |  Page : 27-31

Evaluation of intravitreal corticosteroids as an adjuvant to bevacizumab for diabetic macular edema using electroretinogram


Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Correspondence Address:
Hesham A Enany
Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-9173.157786

Rights and Permissions

Purpose The aim of this study was to investigate electroretinogram changes after intravitreal injection of bevacizumab with or without adjuvant intravitreal corticosteroids for diabetic macular edema. Patients and methods This prospective randomized study evaluated multifocal electroretinogram (MFERG) changes in 60 eyes of 45 diabetic patients who had clinically significant macular edema after treatment with intravitreal bevacizumab (IVB) with or without corticosteroids. Preoperative and postoperative clinical examination, fluorescein angiography, optical coherence tomography, and MFERG were carried out for all cases. The patients were divided into three groups and each group included 20 eyes. The first group was treated with IVB injection alone, the second group was treated with IVB and triamcinolon injection, and the third group was treated with IVB and dexamathosone. The follow-up was carried out up to 3 months. Results The mean visual acuity improved in the three groups, and the mean foveal thickness was reduced in the three groups. As regards MFERG-C, P1 amplitudes increased and P1 peak time (ms) was shortened in the three groups. Intraocular pressure rise occurred in 10% of cases in the second group and in 5% of cases of the third group. Conclusion Diabetic macular edema can be treated with bevacizumab alone, as the use of adjuvant corticosteroids has many complications.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed474    
    Printed23    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal